Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Ascending Dose Study of DS-3032b in Japanese Subjects with Advanced Solid Tumors or Lymphomas
jRCT2080222642Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of milademetan in Nonhematologic neoplasms and lymphoma, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Safety and tolerability of milademetan (DS-3032b). Started Nov 2014; status: completed.
02
Drugs
milademetan
03
Conditions
Nonhematologic neoplasmslymphoma
Beyond the preview
Go deeper on jRCT2080222642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222642.